Log in

LUCD Lucid Diagnostics Inc. NASDAQ · United States

Lucid Diagnostics (LUCD) news

Latest Lucid Diagnostics news

We have not published a story on Lucid Diagnostics yet. When there is news, it will appear here.

Lucid Diagnostics annual financials

LineFY2025FY2024
Revenue$4.3 million
Research and development$5.7 million$6.0 million
Net income (loss)-$58.0 million-$45.5 million
Cash from operations-$46.5 million-$44.1 million
Cash and equivalents$22.4 million

Latest balance sheet, Sep 30, 2025 (10-Q): cash and equivalents $47.3 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Lucid Diagnostics

What is the ticker symbol of Lucid Diagnostics?

Lucid Diagnostics Inc. trades under the ticker LUCD on NASDAQ.

Where is Lucid Diagnostics listed?

Lucid Diagnostics Inc. is listed on NASDAQ.

Which country or territory is Lucid Diagnostics listed under?

Our directory records Lucid Diagnostics Inc. under United States.

Does aibio.space cover Lucid Diagnostics?

aibio.space lists Lucid Diagnostics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Lucid Diagnostics profitable?

Lucid Diagnostics Inc. reported a net loss of $58.0 million for the fiscal year ended Dec 31, 2025, and used $46.5 million of cash in operations, per its annual report to the SEC.

How much does Lucid Diagnostics spend on research and development?

$5.7 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Lucid Diagnostics have?

$47.3 million in cash at Sep 30, 2025, per its 10-Q.

Which other companies' news mentions Lucid Diagnostics?

Lucid Diagnostics is named in 1 of our story about other companies, most recently: "PAVmed reports second quarter 2026 results and Lucid coverage policy" (Aug 14, 2026). Source.

How can I follow Lucid Diagnostics (LUCD) news?

Press Follow on this page to add Lucid Diagnostics to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Lucid Diagnostics so far, in Company Updates.

Investor discussion: Lucid Diagnostics

Members talk about Lucid Diagnostics (LUCD). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Lucid Diagnostics, newest first. Each line links the filing it comes from.

  1. Financings

    Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03,5.03,9.01). Source

  2. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:LUCD on TradingView.

Listing details

Lucid Diagnostics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LUCD, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Lucid Diagnostics Inc.
Ticker
LUCD
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.